Method for diagnosing and treating dysautonomia and other dysautonomic conditions
AssigneeCuremark, LLC
InventorJoan M. Fallon
Life of this patent
Estimating the term…
Abstract
A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.
Claims25
A pharmaceutical preparation to treat a dysautonomic disorder in an individual comprising a therapeutically effective amount of digestive enzymes, wherein the digestive enzymes comprise protease, amylase and lipase, wherein lipase is present in the pharmaceutical composition in an amount of from about 4,000 to about 80,000 USP units/dose.
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating an individual having a dyautonomic disorder comprising:
- measuring a level of fecal chymotrypsin in a stool sample of the individual using a technique selected from the group consisting of:
- enzymatic photospectrometry, colorimetry, treatment with substrates, assays, and a combination thereof;
- comparing the level of fecal chymotrypsin with a normal fecal chymotrypsin level;
- and administering the digestive enzymes to the individual if the level of fecal chymotrypsin in the individual is less than the normal fecal chymotrypsin level;
- and
- administering to the individual a therapeutically effective amount of pharmaceutical composition comprising digestive enzymes, wherein the digestive enzymes comprise protease, amylase and lipase, wherein lipase is present in the pharmaceutical composition in an amount of from about 4,000 to about 80,000 USP units/dose.
(canceled)
(canceled)
A method of treating an individual having a dysautonomic disorder having a subnormal level of fecal chymotrypsin, comprising administering to the individual a therapeutically effective amount of pharmaceutical composition comprising digestive enzymes, wherein the digestive enzymes comprise protease, amylase and lipase, wherein lipase is present in the pharmaceutical composition in an amount of from about 4,000 to about 80,000 USP units/dose.
Dependencies are inferred from the claim text.